Extended-Release Buprenorphine Clinical Use Criteria

In order to promote access to Sublocade, Extended Release Buprenorphine (XRB), MaineCare may engage in rulemaking. In the meantime, providers may bill the medical benefit for XRB without Prior Authorization (PA) if their documentation meets the criteria outlined below. The criteria will be available on the Preferred Drug List after the July 2023 update. Failure to meet these criteria could result in sanctions.    

Coverage of Medications for Treatment of Opioid Use Disorder in Pregnancy

MaineCare covers brand name Suboxone film and generic buprenorphine/naloxone tablets as “Preferred” covered products for treatment of opioid use disorder (OUD) as they are the most cost-effective forms of treatment on the MaineCare Preferred Drug List (PDL). Providers may choose to prescribe buprenorphine/naloxone combination product or buprenorphine monotherapy for patients who are pregnant.      

Annual 1115 Substance Use Disorder (SUD) Waiver Post Award Forum

In July 2022, the Office of MaineCare Services received federal approval to expand services for MaineCare-enrolled parents with SUD, who are involved with Child Protective Services (CPS), or at risk of being involved with CPS. The expanded services are available through three pilot programs under a Medicaid SUD 1115 Waiver first approved by CMS on December 22, 2020, which allows federal Medicaid reimbursement for SUD treatment in facilities with more than 16 beds.

Attention Providers: Updating Your Facility License Under Title 5

Providers whose facility license is under a Title 5 review may use their Title 5 notice to extend their enrollment with MaineCare in MIHMS by six months, and for every six months thereafter, until the Title 5 review is resolved. Providers must complete this update by submitting a maintenance case via the Health PAS Online Portal. Providers can utilize the Provider Maintenance User Guide for a step-by-step guide for submitting a Title 5 Maintenance Case.

Subscribe to